Shares of Cytos Biotechnology Ltd. plunged 32.8 percent on the Swiss stock exchange after the biotech said its vaccine candidate to treat hypertension, CYT006-AngQb, failed in a Phase IIa study to reduce patients' ambulatory blood pressures. (BioWorld Today) Read More
